Parr Christian, Watkins Gareth, Mansel Robert E, Jiang Wen G
Metastasis Research Group, University Department of Surgery, University of Wales College of Medicine, Cardiff, United Kingdom.
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):202-11. doi: 10.1158/1078-0432.ccr-0553-3.
Hepatocyte growth factor (HGF) stimulates tumor cell-cell interactions, matrix adhesion, migration, invasion, and angiogenesis. This factor is produced as an inactive precursor called pro-HGF, which requires proteolytic conversion, by HGF activator (HGFA) and matriptase, to evoke a biological response. Two new HGFA inhibitors, HAI-1 and HAI-2, inhibit the generation of biologically active HGF, through their interaction with HGFA. This study determined the expression of this HGF regulatory system in breast cancer. We examined HGF, the HGF receptor (c-Met), HGFA, matriptase, and the activation inhibitors (HAI-1 and HAI-2), tissues from patients with breast cancer.
Breast cancer tissue (n = 100) and normal background tissue (n = 20) was obtained immediately after surgery. The median follow-up for the patients was 72 months. HGF, c-Met, HGFA, matriptase-1, HAI-1, and HAI-2 expression was quantified using real-time quantitative PCR. The distribution of these factors in mammary tissues was also examined through immunohistochemistry.
The breast cancer specimens expressed a significantly higher level of HGF, c-Met, HGFA, HAI-1, and HAI-2, but not matriptase, compared with the normal background tissues. Tumor tissues from node-positive patients expressed a higher level of HGFA than from the patients without nodal involvement. Interestingly, HAI-2 was expressed to a lower degree in positive nodes than that of the node-negative breast cancer tissues. HAI-1 and HAI-2 were both significantly reduced in grade 3 tumors compared with the well-differentiated tumors. In addition, on comparison of Tumor-Node-Metastasis (TNM) classification groups, HAI-2 was also found to be statistically lower in the TNM 3 breast cancer group when compared with TNM groups 1 and 2, thus associated with a poor prognosis.
This study shows that there are aberrant levels of HGF, c-Met, HGFA, HAI-1, and HAI-2 expressed in breast cancer tissues compared with background breast tissue. HAI-1 and HAI-2 are expressed to a significantly lower level in poorly differentiated breast tumors, and HAI-2 is also inversely correlated with nodal involvement and tumor spread. Overall a low level of HAI-2 in the breast cancer tissues was associated with an overall poor outlook. Therefore, the HGF regulatory system may have an important role in the progression of breast cancer.
肝细胞生长因子(HGF)可刺激肿瘤细胞间相互作用、基质黏附、迁移、侵袭及血管生成。该因子以一种名为前HGF的无活性前体形式产生,需要通过HGF激活剂(HGFA)和matriptase进行蛋白水解转化,以引发生物学反应。两种新的HGFA抑制剂,HAI-1和HAI-2,通过与HGFA相互作用抑制生物活性HGF的产生。本研究确定了该HGF调节系统在乳腺癌中的表达情况。我们检测了乳腺癌患者组织中的HGF、HGF受体(c-Met)、HGFA、matriptase以及激活抑制剂(HAI-1和HAI-2)。
术后立即获取乳腺癌组织(n = 100)和正常背景组织(n = 20)。患者的中位随访时间为72个月。使用实时定量PCR对HGF、c-Met、HGFA、matriptase-1、HAI-1和HAI-2的表达进行定量。还通过免疫组织化学检测了这些因子在乳腺组织中的分布。
与正常背景组织相比,乳腺癌标本中HGF、c-Met、HGFA、HAI-1和HAI-2的表达水平显著更高,但matriptase的表达无差异。淋巴结阳性患者的肿瘤组织中HGFA表达水平高于无淋巴结受累的患者。有趣的是,HAI-2在阳性淋巴结中的表达程度低于淋巴结阴性的乳腺癌组织。与高分化肿瘤相比,3级肿瘤中HAI-1和HAI-2均显著降低。此外,在比较肿瘤-淋巴结-转移(TNM)分类组时,发现TNM 3期乳腺癌组中的HAI-2在统计学上也低于TNM 1期和2期组,因此与预后不良相关。
本研究表明,与乳腺背景组织相比,乳腺癌组织中HGF、c-Met、HGFA、HAI-1和HAI-2的表达水平异常。HAI-1和HAI-2在低分化乳腺癌肿瘤中的表达水平显著较低,并且HAI-2也与淋巴结受累和肿瘤扩散呈负相关。总体而言,乳腺癌组织中HAI-2水平较低与整体预后不良相关。因此,HGF调节系统可能在乳腺癌进展中起重要作用。